StockNews.com lowered shares of AC Immune (NASDAQ:ACIU – Free Report) from a buy rating to a hold rating in a research note issued to investors on Tuesday.
Separately, HC Wainwright reaffirmed a buy rating and issued a $16.00 price objective on shares of AC Immune in a research note on Wednesday, September 18th.
Read Our Latest Stock Report on AC Immune
AC Immune Price Performance
AC Immune (NASDAQ:ACIU – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $91.60 million. Research analysts anticipate that AC Immune will post -0.89 EPS for the current fiscal year.
Hedge Funds Weigh In On AC Immune
Institutional investors and hedge funds have recently modified their holdings of the business. Platinum Investment Management Ltd. lifted its holdings in shares of AC Immune by 14.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after purchasing an additional 193,123 shares in the last quarter. Avidity Partners Management LP increased its position in shares of AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock valued at $22,345,000 after purchasing an additional 1,499,280 shares during the last quarter. BVF Inc. IL increased its position in shares of AC Immune by 96.2% during the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock valued at $72,856,000 after purchasing an additional 7,142,857 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 96.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock valued at $56,000 after purchasing an additional 9,334 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than AC Immune
- 3 Ways To Invest In Coffee, Other Than Drinking It
- When Is the Best Time to Invest in Mutual Funds?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is NVIDIA Stock in a Correction or Consolidation?
- With Risk Tolerance, One Size Does Not Fit All
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.